Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2023-12-14 00:00:00 ET · period of report 2023-12-12 · accession 0001209191-23-058683 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-14 | 2023-12-12 | NBIX | ROBERTS EIRY | Chief Medical Off | M - OptEx | $81.05 | +13.9K | 36.5K | +62% | +$1.13M |
| DM | 2023-12-14 | 2023-12-12 | NBIX | ROBERTS EIRY | Chief Medical Off | S - Sale+OE | $120.30 | -13.9K | 29.5K | -32% | -$1.68M |
| DM | 2023-12-14 | 2023-12-12 | NBIX | ROBERTS EIRY | Chief Medical Off | M - OptEx | $81.05 | -13.9K | 46.4K | -23% | -$1.13M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-12 | M | A | 6,947 | $81.05 | 36,468 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-12 | S | D | 6,978 | $120.30 | 29,521 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2023-12-12 | M | A | 6,978 | $81.05 | 36,499 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-12 | S | D | 6,947 | $120.31 | 29,521 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) 28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. |
| 5 | Derivative | Non-Qualified Stock Option | 2023-12-12 | M | D | 6,947 | $81.05 | 39,440 | D | $81.05 · — to 2029-02-02 | 6,947 Common Stock | (F4) Option granted February 7, 2019 and vested monthly over four years. |
| 6 | Derivative | Non-Qualified Stock Option | 2023-12-12 | M | D | 6,978 | $81.05 | 46,387 | D | $81.05 · — to 2029-02-07 | 6,978 Common Stock | (F4) Option granted February 7, 2019 and vested monthly over four years. |